Accenture stock Outperform rating upheld amid strong GenAI bookings By Investing.com

On Friday, RBC Capital Markets adjusted its price target for shares of Accenture plc (NYSE: NYSE:), increasing it to $389.00 from the previous $377.00. The firm maintained its Outperform rating on the stock. The revision follows Accenture’s announcement of robust financial performance and forward-looking guidance.

The company’s recent success has been attributed to the revenue recognition from larger projects initiated in earlier periods. This has led to a significant sequential improvement, especially within the Strategy & Consulting segment. The firm’s growth trajectory is further evidenced by the substantial increase in bookings and revenue for its GenAI product line.

In the fiscal year 2024, GenAI bookings have surpassed $3 billion, with revenues around $900 million. This marks a considerable rise from the $300 million in bookings and $100 million in revenue reported in the fiscal year 2023. The increase reflects Accenture’s strong positioning in the market and its ability to capitalize on emerging technology trends.

Accenture’s solid results and optimistic guidance demonstrate the company’s consistent performance and its strategic focus on high-growth areas. The updated price target from RBC Capital Markets signifies confidence in Accenture’s business model and its potential for continued financial success.

In other recent news, Accenture has demonstrated robust financial performance in fiscal year 2024. The company’s bookings increased by 14% to reach a record $81 billion, and revenue grew by 2% to total $65 billion. Adjusted earnings per share also saw a moderate rise to $11.95.

For fiscal year 2025, Accenture has projected revenues between $16.85 billion and $17.45 billion, anticipating growth rates of 3% to 6% in local currency. Operating margins are expected to be between 15.6% and 15.8%, with earnings per share ranging from $12.55 to $12.91.

In terms of recent analyst reviews, Jefferies increased Accenture’s price target to $355, maintaining a Hold rating. Piper Sandler upgraded Accenture from Neutral to Overweight, raising the price target to $395. Meanwhile, Goldman Sachs maintained a neutral stance on Accenture shares.

In other company news, Accenture plans to invest approximately $3 billion in acquisitions and return at least $8.3 billion to shareholders. The company also added approximately 24,000 employees in Q4, primarily in technology roles, and expects to see significant growth in GenAI bookings.

InvestingPro Insights

Accenture’s (NYSE: ACN) fiscal year 2024 is shaping up to be a promising period for the company, as reflected by RBC Capital Markets’ increased price target and the firm’s strong financial performance. InvestingPro data shows that Accenture has a market capitalization of $222.87 billion, underscoring its significant presence in the industry. The company’s Price/Earnings (P/E) ratio stands at 31.99, indicating investor confidence in its earnings potential. Moreover, the company’s revenue growth over the last twelve months has been modest at 1.22%, reflecting steady business expansion.

InvestingPro Tips highlight Accenture’s stability and potential for growth. The company has raised its dividend for 5 consecutive years, demonstrating a commitment to returning value to shareholders. Additionally, with 12 analysts revising their earnings upwards for the upcoming period, there is an optimistic sentiment surrounding Accenture’s financial prospects. The stock is known for its low price volatility, which might appeal to investors looking for stable returns. For those interested in deeper analysis, there are 13 additional InvestingPro Tips available, providing further insights into Accenture’s financial health and market performance.

As Accenture continues to focus on high-growth areas and expand its technology consulting offerings, these metrics and insights from InvestingPro provide a comprehensive view of the company’s financial standing and market potential. Investors may find this information valuable as they assess Accenture’s performance and consider the stock’s place in their portfolios.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.